DNTH241220P40000
- 0.00
- 0.000.00%
Dianthus Therapeutics Newsroom
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
Oppenheimer Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $52
Dianthus Therapeutics Price Target Raised to $52.00/Share From $48.00 by Oppenheimer
Dianthus Therapeutics Is Maintained at Outperform by Oppenheimer
Dianthus Therapeutics Analyst Ratings
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
Baird Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $58
Guggenheim Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating
Dianthus Therapeutics Analyst Ratings
Oppenheimer Initiates Dianthus Therapeutics at Outperform With $48 Price Target
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Analyst Ratings
Promising Clinical Developments Bolster Buy Rating for Dianthus Therapeutics
Wedbush Remains a Buy on Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Receives 'Buy' Rating on Strong Financials and Promising Drug Pipeline
Baird Starts Dianthus Therapeutics With Outperform Rating, $58 Price Target
Dianthus Therapeutics Analyst Ratings
Baird Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $58
Buy Rating on Dianthus Therapeutics Supported by Promising MMN Treatment Data and Market Potential